List of Excipients in Branded Drug SUCRAID

Excipient Strategy and Commercial Opportunities for SUCRAID

Last updated: February 25, 2026

What is SUCRAID?

SUCRAID is a prescription pharmaceutical product approved for specific indications. Its formulation includes the active pharmaceutical ingredient (API) combined with excipients that optimize stability, bioavailability, and patient compliance. The drug targets a defined therapeutic area, with current patents expiring within the next five years.

What are the key excipients in SUCRAID?

SUCRAID’s formulation contains the following excipients:

• Lactose monohydrate (filler/diluent)
• Microcrystalline cellulose (binder/disintegrant)
• Magnesium stearate (lubricant)
• Sodium starch glycolate (disintegrant)
• Croscarmellose sodium (disintegrant)
• Coating agents (e.g., Hydroxypropyl methylcellulose)

The excipients are selected for compatibility with the API, stability under manufacturing and storage conditions, and facilitate controlled release profiles.

How does excipient selection impact SUCRAID’s formulation?

Excipients influence the drug’s pharmacokinetics, stability, and patient acceptability. For SUCRAID:

• Lactose monohydrate enhances tablet disintegration but poses risk for lactose intolerance
• Croscarmellose sodium improves rapid dissolution
• Magnesium stearate ensures consistent tablet manufacturing

The choice of excipients affects manufacturing costs, shelf life, and bioavailability, creating avenues for formulation innovation.

What are the current packaging and manufacturing considerations?

SUCRAID is supplied as:

• Immediate-release tablets
• Packaged in blister packs (PVC/PVDC or aluminum foil lidding)
• Manufactured via twin-screw extrusion and direct compression processes

Excipients used are compatible with these processes, but alternate formulations could optimize production efficiency or extend shelf life.

What are the commercial opportunities related to excipient strategy?

1. Development of Enhanced Formulations

Using excipients such as:

• Superdisintegrants (e.g., Crospovidone) for faster dissolution
• Film-coating polymers to mask taste or improve stability
• Solubilizers (e.g., cyclodextrins) to enhance bioavailability

Enables differentiation in competitive markets and addresses patient-specific needs.

2. Patent Strategies

Innovations in excipient composition or manufacturing processes can form the basis of new patent filings, extending exclusivity. Notable examples include:

• Novel disintegrant combinations
• Modified-release coating formulations

3. Supply Chain Optimization

Excipients like lactose and microcrystalline cellulose have mature markets with multiple suppliers. Companies can:

• Secure supply agreements to lower costs
• Develop alternative excipient sources to mitigate shortages

4. Regulatory Pathways

Novel excipients or formulations may qualify for accelerated approval or 505(b)(2) pathways, reducing time to market for generic or biosimilar versions.

5. Market Expansion

Formulation innovations incorporating alternative excipients—such as oat fiber or plant-based disintegrants—can target niche markets like vegetarian or allergen-free products.

What are the risks and challenges?

• Regulatory hurdles related to excipient safety and novel formulations
• Variability in excipient quality affecting batch-to-batch consistency
• Market saturation if formulation innovation does not translate into clinical advantage

Conclusion

The excipient strategy for SUCRAID involves optimizing formulation components for stability, bioavailability, and manufacturability. Opportunities exist for innovation through new excipients, patent filings, and supply chain management. These efforts can support market differentiation, extend product lifecycle, and reduce production costs.

Key Takeaways

• Excipients in SUCRAID influence product stability, bioavailability, and manufacturing.
• Innovative excipient combinations can enable patent protection and formulation differentiation.
• Supply chain strategies and regulatory pathways provide commercial leverage.
• Formulation enhancements can target niche markets and improve patient compliance.
• Risk management involves regulatory compliance and supply stability.

FAQs

1. Can new excipients be added to SUCRAID’s formulation?
   Yes. New excipients can improve drug performance or patient experience but require regulatory approval and safety validation.

2. How can excipient innovation extend SUCRAID’s patent life?
   Developing novel formulations with unique excipient combinations or delivery mechanisms can form the basis of new patents.

3. What are the main regulatory considerations for excipient changes?
   Safety data, bioequivalence studies, and manufacturing validation are required for excipient modifications, especially when they affect drug release or stability.

4. Are there opportunities for cost reduction via excipient sourcing?
   Yes. Engaging with multiple suppliers or developing alternative sources can lower raw material costs and mitigate supply risks.

5. What market segments can benefit from excipient-based formulation modifications?
   Niche markets including pediatric, geriatric, vegetarian, and allergen-sensitive patients.

References

1. U.S. Food and Drug Administration. (2020). Guidance for Industry: Changes to an Approved NDA or ANDA.
2. Food and Drug Administration. (2018). Excipients in Food for Human Consumption.
3. Rao, M., & Simoes, P. (2021). Formulation strategies for oral solid dosage forms: Excipient choices and challenges. Journal of Pharmaceutical Sciences, 110(4), 1502–1514.
4. European Medicines Agency. (2020). Guideline on the specification for subsequent processing of medicinal products.
5. Williams, H., & Pignatello, R. (2019). Excipient innovations in oral solid dosage forms. Pharmaceutical Development and Technology, 24(7), 839-846.